Rachelle Lanciano

List of Publications by Year
in descending order

72 papers	3,158 citations	147801 31 h-index	149698 56 g-index
72 all docs	72 docs citations	72 times ranked	2942 citing authors

#	Article	IF	Citations
1	CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 652646.	2.8	7
2	Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up. Frontiers in Oncology, 2020, 10, 1505.	2.8	0
3	Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Nonsmall Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations. Advances in Radiation Oncology, 2020, 5, 984-993.	1.2	9
4	Volume effects in radiosurgical spinal cord dose tolerance: how small is too small?. Journal of Radiation Oncology, 2019, 8, 53-61.	0.7	8
5	Stereotactic Body Radiotherapy (SBRT) for liver metastasis â€“ clinical outcomes from the international multi-institutional RSSearchÂ® Patient Registry. Radiation Oncology, 2018, 13, 26.	2.7	142
6	Clinical evidence for dose tolerance of the central nervous system in hypofractionated radiotherapy. Journal of Radiation Oncology, 2018, 7, 293-305.	0.7	2
7	The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event. Journal of Radiation Oncology, 2017, 6, 31-37.	0.7	4
8	Lung metastases treated with stereotactic body radiotherapy: the RSSearchÂ® patient Registryâ€™s experience. Radiation Oncology, 2017, 12, 35.	2.7	68
9	Single Institutional Experience of Stereotactic Radiosurgery Alone for First Brain Metastatic Event and Salvage of Second Brain Metastatic Event in a Community Setting with Review of the Literature. Frontiers in Oncology, 2017, 7, 32.	2.8	3
10	Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database. Frontiers in Oncology, 2017, 7, 185.	2.8	11
11	The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups. Frontiers in Oncology, 2016, 6, 184.	2.8	17
12	Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy. Frontiers in Oncology, 2016, 6, 249.	2.8	27
13	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecologic Oncology, 2016, 143, 294-301.	1.4	31
14	Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. Journal of Radiation Oncology, 2016, 5, 187-195.	0.7	10
15	Predictors of long-term survival for localized prostate cancer treated with high-dose IMRT stratified by NCCN 2015 guidelines in a community hospital setting. Journal of Radiation Oncology, 2016, 5, 95-101.	0.7	0
16	SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. Frontiers in Oncology, 2015, 5, 101.	2.8	15
17	Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience. Frontiers in Oncology, 2015, 5, 106.	2.8	34
18	Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting. Frontiers in Oncology, 2015, 5, 146.	2.8	13

#	Article	IF	Citations
19	Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. Journal of Clinical Oncology, 2015, 33, 2136-2142.	1.6	135
20	Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. Journal of Radiation Oncology, 2015, 4, 65-70.	0.7	44
21	SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines. Frontiers in Oncology, 2014, 4, 312.	2.8	26
22	Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. Gynecologic Oncology, 2014, 135, 208-212.	1.4	85
23	Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. Journal of Radiation Oncology, 2013, 2, 63-70.	0.7	70
24	Effect of Fractionation in Stereotactic Body Radiation Therapy Using the Linear Quadratic Model. International Journal of Radiation Oncology Biology Physics, 2013, 86, 150-156.	0.8	12
25	Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors. Frontiers in Oncology, 2012, 2, 23.	2.8	43
26	Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: A Gynecologic Oncology Group study. Gynecologic Oncology, 2011, 121, 542-545.	1.4	33
27	Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology, 2010, 202, 283.e1-283.e7.	1.3	17
28	Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. Gynecologic Oncology, 2010, 117, 270-275.	1.4	39
29	Red Shell: Defining a High-Risk Zone of Normal Tissue Damage in Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 903-909.	0.8	33
30	A â€œRed Shellâ€•concept of increased radiation damage hazard to normal tissues just outside the PTV target volume. Radiotherapy and Oncology, 2010, 94, 384.	0.6	5
31	Retrospective Analysis of Concomitant Cisplatin During Radiation in Patients Aged 55 Years or Older for Treatment of Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2009, 19, 1258-1263.	2.5	26
32	Surgical versus radiographic determination of paraâ€aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma. Cancer, 2008, 112, 1954-1963.	4.1	177
33	A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 287-292.	1.1	41
34	Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma?. Gynecologic Oncology, 2007, 105, 427-433.	1.4	86
35	Phase II Trial of Preoperative Chemoradiation With a Hyperfractionated Radiation Boost in Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 435-441.	1.3	19
36	Randomized Comparison of Weekly Cisplatin or Protracted Venous Infusion of Fluorouracil in Combination With Pelvic Radiation in Advanced Cervix Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 8289-8295.	1.6	168

#	Article	IF	Citations
37	OPTIMIZING RADIATION TREATMENT FOR CERVICAL CANCER. Surgical Clinics of North America, 2001, 81, 859-870.	1.5	2
38	The Efficacy and Safety of Once-Daily KytrilÂ® (Granisetron Hydrochloride) Tablets in the Prophylaxis of Nausea and Emesis Following Fractionated Upper Abdominal Radiotherapy. Cancer Investigation, 2001, 19, 763-772.	1.3	45
39	Optimizing radiation parameters for cervical cancer. Seminars in Radiation Oncology, 2000, 10, 36-43.	2.2	23
40	CURRENT DEVELOPMENTS IN THE TREATMENT OF NEWLY DIAGNOSED CERVICAL CANCER. Hematology/Oncology Clinics of North America, 1999, 13, 275-303.	2.2	11
41	Prognostic Value of CA 19-9 Levels in Patients with Carcinoma of the Pancreas Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 393-396.	0.8	52
42	Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics, 1998, 42, 43-50.	0.8	54
43	Intra- and Perioperative Complications Associated with Tandem and Colpostat Application for Cervix Cancer. Gynecologic Oncology, 1997, 64, 224-229.	1.4	29
44	Over 20 years of progress in radiation oncology: Cervical cancer. Seminars in Radiation Oncology, 1997, 7, 121-126.	2.2	14
45	The Relationship of Local and Distant Failure from Endometrial Cancer: Defining a Clinical Paradigm. Gynecologic Oncology, 1997, 66, 411-416.	1.4	52
46	Wound complications after resection and immediate postoperative brachytherapy in the management of soft-tissue sarcomas. Annals of Surgical Oncology, 1996, 3, 51-56.	1.5	22
47	2047 Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 1996, 36, 301.	0.8	0
48	2102 The effect of adjuvant megace on outcome for stage III endometrial carcinoma: A multivariate analysis. International Journal of Radiation Oncology Biology Physics, 1996, 36, 327.	0.8	0
49	37 The relationship of local and distant failure from endometrial cancer: Defining a clinical paradigm. International Journal of Radiation Oncology Biology Physics, 1996, 36, 177.	0.8	1
50	Postoperative radiation therapy for surgically staged endometrial cancer: Impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome. International Journal of Radiation Oncology Biology Physics, 1995, 33, 837-842.	0.8	32
51	Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: Accuracy and reproducibility. International Journal of Radiation Oncology Biology Physics, 1995, 33, 111-118.	0.8	61
52	Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: A phase II study from radiation therapy oncology group 85-04. Annals of Surgical Oncology, 1995, 2, 295-302.	1.5	29
53	The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: Analysis of 32 cases. Obstetrics and Gynecology, 1995, 86, 955-959.	2.4	26
54	Improved Treatment Planning for the Syed-Neblett Template Using Endorectal-Coil Magnetic Resonance and Intraoperative (Laparotomy/Laparoscopy) Guidance: A New Integrated Technique for Hysterectomized Women with Vaginal Tumors. Gynecologic Oncology, 1995, 56, 255-261.	1.4	50

#	Article	IF	Citations
55	Adjuvant Treatment for Endometrial Cancer: Who Needs It?. Gynecologic Oncology, 1995, 57, 135-137.	1.4	18
56	Treatment-Related Myelodysplastic Syndrome Following Abdominopelvic Radiotherapy for Endometrial Cancer. Gynecologic Oncology, 1995, 57, 430-432.	1.4	2
57	Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis.. Journal of Clinical Oncology, 1994, 12, 510-515.	1.6	152
58	Perioperative morbidity of intracavitary gynecologic brachytherapy. International Journal of Radiation Oncology Biology Physics, 1994, 29, 969-974.	0.8	25
59	Inaccuracies in using the lumpectomy scar for planning electron boosts in primary breast carcinoma. International Journal of Radiation Oncology Biology Physics, 1994, 30, 43-48.	0.8	129
60	Combined modality treatment for carcinomas of the uterine cervix and vulva. Current Opinion in Oncology, 1994, 6, 524-530.	2.4	6
61	Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer, 1993, 71, 3697-3702.	4.1	124
62	Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. International Journal of Radiation Oncology Biology Physics, 1993, 27, 825-830.	0.8	175
63	The justification for a surgical staging system in endometrial carcinoma. Radiotherapy and Oncology, 1993, 28, 189-196.	0.6	41
64	Radiotherapy for gynecologic malignancies. Current Opinion in Oncology, 1992, 4, 930-938.	2.4	1
65	Intraoperative liver radiation after partial hepatectomy in a rat model. Journal of Surgical Research, 1992, 53, 287-292.	1.6	5
66	Surgical complications of intraoperative radiation therapy: The radiation therapy oncology group experience. Journal of Surgical Oncology, 1992, 50, 209-215.	1.7	46
67	A reappraisal of the international federation of gynecology and obstetrics staging system for cervical cancer. A study of patterns of care. Cancer, 1992, 69, 482-487.	4.1	45
68	Influence of age, prior abdominal surgery, fraction size, and dose on complications after radiation therapy for squamous cell cancer of the uterine cervix. A patterns of care study. Cancer, 1992, 69, 2124-2130.	4.1	116
69	Radiation therapy for gynecologic cancer. Current Opinion in Oncology, 1990, 2, 885-892.	2.4	1
70	The results of radiotherapy for orbital pseudotumor. International Journal of Radiation Oncology Biology Physics, 1990, 18, 407-411.	0.8	72
71	The patterns of care outcome study for cancer of the uterine cervix results of the second national practice survey. Cancer, 1990, 66, 2451-2456.	4.1	191
72	Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecologic Oncology, 1990, 39, 368-373.	1.4	46